$0.02
(Market cap
$600 Mln
Revenue (TTM)
$317 Mln
P/E Ratio
35.3
P/B Ratio
1.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$0.2
-
Face value
--
-
Shares outstanding
65,386,191
8 Years Aggregate
CFO
$-222.69 Mln
EBITDA
$-1,089.91 Mln
Net Profit
$-1,076.20 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Arvinas (ARVN)
| -22.4 | 10.8 | 2.4 | 19.0 | -30.4 | -35.9 | -- |
|
BSE Sensex
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Arvinas (ARVN)
| -38.1 | -53.1 | 20.3 | -58.4 | -3.3 | 106.7 | 219.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Arvinas (ARVN)
|
9.2 | 600.3 | 316.7 | 9.3 | -0.3 | 1.9 | 35.3 | 1.1 |
| 82.4 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 263.0 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 70.9 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.6 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 106.5 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 359.4 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 540.0 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 594.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 350.3 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Arvinas (ARVN)
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein... degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut. Read more
-
Chairperson, CEO & President
Dr. John G. Houston Ph.D.
-
Chairperson, CEO & President
Dr. John G. Houston Ph.D.
-
Headquarters
New Haven, CT
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Arvinas (ARVN)
What is the current share price of Arvinas Inc (ARVN) Today?
The share price of Arvinas Inc (ARVN) is $9.20 (NASDAQ) as of 31-Aug-2026 16:00 EDT. Arvinas Inc (ARVN) has given a return of -30.36% in the last 3 years.
What is the current PB & PE ratio of Arvinas Inc (ARVN)?
The P/E ratio of Arvinas Inc (ARVN) is 35.31 times as on 28-Aug-2026.
The P/B ratio of Arvinas Inc (ARVN) is 1.07 times as on 28-Aug-2026, a 79 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-9.53 |
1.77 |
2024 |
-6.95 |
2.46 |
2023 |
-6.85 |
3.81 |
2022 |
-6.69 |
3.22 |
2021 |
-23.67 |
5.55 |
What is the 52 Week High and Low of Arvinas Inc (ARVN)?
The 52-week high and low of Arvinas Inc (ARVN) are Rs 14.51 and Rs 6.97 as of 01-Sep-2026.
What is the market cap of Arvinas Inc (ARVN)?
Arvinas Inc (ARVN) has a market capitalisation of $ 600 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Arvinas Inc (ARVN)?
Before investing in Arvinas Inc (ARVN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.